VistaGen Therapeutics, Inc. Repayment/Issuance of Debt (Net)

Repayment/Issuance of Debt (Net) of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Repayment/Issuance of Debt (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Repayment/Issuance of Debt (Net) for the quarter ending December 30, 2020 was $-422 Thousand (a 119.38% increase compared to previous quarter)
  • Year-over-year quarterly Repayment/Issuance of Debt (Net) increased by 185.15%
  • Annual Repayment/Issuance of Debt (Net) for 2020 was $-564 Thousand (a 152.51% increase from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2019 was $-223 Thousand (a 8.67% increase from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2018 was $-205 Thousand (a 11.93% increase from previous year)
  • Twelve month Repayment/Issuance of Debt (Net) ending December 30, 2020 was $-661 Thousand (a 26.0% increase compared to previous quarter)
  • Twelve month trailing Repayment/Issuance of Debt (Net) increased by 17.35% year-over-year
Trailing Repayment/Issuance of Debt (Net) for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$-661 Thousand $-525 Thousand $-420 Thousand $-564 Thousand
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Repayment/Issuance of Debt (Net) of VistaGen Therapeutics, Inc.

Most recent Repayment/Issuance of Debt (Net)of VTGN including historical data for past 10 years.

Interactive Chart of Repayment/Issuance of Debt (Net) of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. Repayment/Issuance of Debt (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-0.42 $-0.19 $0.1 $-0.15 $-0.56
2019 $-0.29 $-0.09 $-0.04 $-0.06 $-0.22
2018 $-0.07 $-0.07 $-0.03 $-0.05 $-0.21
2017 $-0.06 $-0.06 $-0.03 $-0.04 $-0.18
2016 $-0.04 $-0.04 $-0.07 $-0.03 $-0.11
2015 $-0.04 $-0.04 $-0.01 $-0.07 $-0.31
2014 $-0.04 $-0.09 $-0.11 $-0.03 $0.09
2013 $-0.03 $0.2 $-0.04 $0.88 $2.71
2012 $0.79 $1.04 $-0.01 $0.37 $-0.31
2011 $-0.21 $-0.14 $-0.33 $0.84 $0.84
2010 $0.79 $0.23 $0.0

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.